Peptide laws by state: what states can and can't change, and what's actually on the books

Who controls what

Peptide legality in the United States has two layers.

Layer	Who	What it decides
Federal	FDA, under the Food, Drug, and Cosmetic Act	Whether a peptide is an approved drug, may be compounded (sections 503A and 503B), or is an unapproved new drug. Also import and interstate sale.
State	Legislatures, boards of pharmacy, medical and nursing boards	Who may prescribe, compound and dispense; pharmacy licensing (including out-of-state pharmacies shipping in); professional discipline.

A state can be stricter than federal law: a board can limit what its licensees do. A state cannot make something lawful that federal law forbids. A peptide sold as “research use only” for people to inject is an unapproved new drug under federal law in every state (why).

States with verified peptide-specific laws

We list a state only when we can link the statute, regulation or official board document.

State	Record	What it does	Status
Louisiana	SB 253, Act 374 (R.S. 37:23.5)	Licensing boards may not prohibit prescribers from providing peptides from a compliant 503B outsourcing facility or 503A pharmacy, or prohibit Louisiana pharmacists from compounding and dispensing peptides in compliance with 21 U.S.C. 353a and USP-NF chapters	Signed May 22, 2026; effective August 1, 2026
Florida	SB 860 (compounded weight-loss medications); HB 877 (compounded drugs and APIs)	Would have regulated sale and distribution of certain compounded drugs	Both died in committee, March 13, 2026. No enacted law

Our Louisiana report has the full text and votes.

Why Louisiana’s law has limits

Act 374 protects prescribers and pharmacists only when the compounding complies with federal law. Under section 503A, a pharmacy may compound from a bulk ingredient only if it is part of an approved drug, has a USP monograph, or is on FDA’s 503A bulks list. As of October 19, 2026, that list (21 CFR 216.23(a)) has six substances, none of them a peptide. FDA’s separate Category 1 list includes a few peptides, such as glutathione and vasoactive intestinal peptide (details). So the law’s real effect depends on federal decisions still pending: FDA’s response to the July 2026 advisory votes and its unpublished interim access policy (explainer).

What we don’t list, and why

Several websites publish state-by-state guides that rank states as “permissive,” “moderate” or “restrictive” for peptides. We could not tie those labels to statutes or board actions, so we do not repeat them. Claims we saw about 2026 peptide bills in other states came from secondary sites without links to bill text. We will add a state when we can verify its record.

How to check your own state

1. Legislature. Search your state legislature’s bill tracker for “peptide” and “compounded.” Check the bill’s last action, not just the filed text. Many bills die in committee.
2. Board of pharmacy. Boards publish bulletins, newsletters and rule changes. Louisiana’s board summarized Act 374 in a July 2026 bulletin.
3. Medical board. Some boards issue position statements on compounded or off-label drugs. A position statement is not a statute, but it shapes discipline.
4. Out-of-state pharmacies. If a clinic ships from another state, that pharmacy usually needs a nonresident license in yours. Your board’s license lookup shows whether it has one.

For the federal side, start with are peptides legal? and FDA status by peptide.